SynOx Therapeutics

SynOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. Founded in November 2020, the company has secured significant funding through Series A and Series B financing rounds, as well as a loan facility with Hercules Capital. SynOx is led by a seasoned team of industry professionals with a successful track record in developing and bringing products to market.

The company is currently initiating a Phase 3 clinical trial (TANGENT) to assess the efficacy and safety of emactuzumab in patients with localized and diffuse TGCT. SynOx's mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs and improve the quality of life of patients with TGCT, a rare and debilitating disease. The company is also exploring the potential use of emactuzumab for other CSF-1 driven and macrophage-mediated diseases.

SynOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumors (TGCT) and other macrophage-driven pathologies. Their mission is to establish emactuzumab as the preferred treatment option for TGCT, addressing unmet medical needs and significantly improving the quality of life for patients suffering from this debilitating disease.

SynOx Therapeutics fosters a culture driven by dedication to patient-centricity, characterized by a passion for delivering life-improving options for those suffering from Tenosynovial Giant Cell Tumours (TGCT) and other macrophage-mediated diseases. The company values a collaborative and supportive work environment where expertise is combined with a strong focus on scientific advancements. This is reflected in its commitment to building a diverse and experienced team of industry professionals, evidenced by its robust hiring process and emphasis on attracting individuals who share the company's mission and values.

SynOx Therapeutics emphasizes building a diverse and inclusive workforce. Their website highlights the diverse backgrounds and experiences of their leadership team, showcasing a commitment to a range of perspectives. While the company doesn't explicitly state a formal diversity, equity and inclusion (DE&I) policy or strategy, their focus on building a skilled team with "passion, dedication and patient-focus" suggests a commitment to creating a welcoming and supportive environment for employees from all backgrounds.